Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE
  4. Inadequate Bowel Prep: The Achilles' Heel of Colorectal Cancer Screening Colonoscopy

MinuteCE®

Inadequate Bowel Prep: The Achilles' Heel of Colorectal Cancer Screening Colonoscopy

Bowel Prep Hesitancy: What's It All About? 

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Comments
  • Overview

    In the battle against colorectal cancer, inadequate bowel preparation emerges as a critical obstacle compromising the effectiveness of screening colonoscopies. Suboptimal prep quality hinders the clear visualization of the colon, leading to missed lesions and reduced diagnostic accuracy. This educational initiative aims to confront this Achilles' heel by emphasizing the importance of thorough bowel prep protocols. By addressing and improving this aspect, healthcare providers can enhance the overall efficacy of colonoscopy screenings, ultimately contributing to better outcomes in colorectal cancer prevention and early detection.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.   

    Host: 
    David A. Johnson, MD 
    Professor of Medicine 
    Chief of Gastroenterology 
    Eastern VA Medical School 
    Norfolk, VA  

    Dr. Johnson has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Research: ISOThrive 

    Faculty:
    Douglas K. Rex, MD, MASGE, MACG, MACP, AGAF
     
    Distinguished Professor Emeritus 
    Indiana University School of Medicine 
    Indianapolis, IN  

    Dr. Rex has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Research: Braintree Laboratories, Erbe USA Inc, Medivators, Olympus Corporation  
    Ownership Interest: Satisfai Health 
    Consulting Fees: Acacia Pharmaceuticals, Boston Scientific, Braintree Laboratories, Medtronic, Norgine, Olympus Corporation

    Aasma Shaukat, MD 
    Professor of Medicine and Population Health 
    NYU Grossman School of Medicine 
    NYU Langone Health 
    New York, NY 

    Dr. Shaukat has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months: 
    Consulting Fees: Freenome Inc, Iterative Health, Universal Dx 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose. 
    • Tim Person has nothing to disclose. 
    • Katie Sheridan has nothing to disclose. 
    • Samantha Keehn has nothing to disclose. 
    • John Maeglin has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Determine a bowel preparation regimen that a patient is most likely to tolerate and achieve adequate bowel cleansing
    • Demonstrate use of strategies to avoid unwanted consequences of inadequate bowel cleansing in preparation for a screening colonoscopy
    • Recognize benchmarks for key quality indicators for colorectal cancer screening by colonoscopy 
  • Target Audience

    This activity is designed to meet the educational needs of gastroenterologists, primary care physicians, nurses, and physician associates.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.00 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 03/20/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.00 contact hours/0.10 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-24-035-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Sebela Pharmaceuticals.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule13 Dec 2024